A meta-analysis that investigated CIP incidence among clinical trial participants with melanoma, NSCLC, or renal cell carcinoma reported an overall incidence of 2.7% during PD-1 inhibitor therapy and an incidence of 0.8% for grades three and higher [6]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.